Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical Trial

Phase

N/A

Condition

Depression

Liver Disorders

Hepatitis

Treatment

Depression and Cognitive Tests

Clinical Study ID

NCT04330508

IEC-D3/2018-866

Ages 18-65
All Genders
Accepts Healthy Volunteers

Study Summary

Minimal hepatic encephalopathy (MHE) is an important clinical variant of hepatic encephalopathy (HE), which occurs in up to 60-70% of patients with cirrhosis. The condition comprises a cognitive impairment, observed in patients with cirrhosis who have no clinical evidence of overt hepatic encephalopathy (OHE). It is associated with an increased incidence of road traffic accidents, reduced quality of life and it affects the ability to perform tasks of daily living. Successful treatment of hepatitis C has been reported to be associated with 62-84% reduction in all-cause mortality (deaths), 68-79% reduction in risk of HCC and 90% reduction in risk of liver transplantation. In addition, studies have shown that viral eradication may improve cognition when given interferon based regimens for HCV. With the available of safe, efficacious, all oral regimens for HCV, we plan to prospectively analyse the change in mood, depression and cognitive function in response to DAA therapy, in relation to outcomes of treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Age 18-65 years and chronic HCV infection.
Group A: Patients with hepatitis C (Non-cirrhotic) [n= 150]
Group B: Patients with hepatitis C related compensated-cirrhosis [n= 150]
Group C: Healthy volunteers [n= 25]

Exclusion

Exclusion Criteria:

Current overt hepatic encephalopathy or during the last 1 month
TIPS (transjugular intra- hepatic porto-systemic shunt)
elective surgery planned within the next 8 weeks
unable to give informed consent
HIV infection
chronic respiratory insufficiency
current infection and receiving antibiotics
renal failure (serum creatinine ≥ 1.5 mg/l)
hepatocellular carcinoma,
patient with other neurological disease
intake of sedatives, antidepressants, benzodiazepines, or benzodiazepines-antagonists (flumazenil, neuromuscular blocking agents)

Study Design

Depression and Cognitive Tests

March 01, 2018

December 31, 2021

Study Description

Investigations will be performed according to the Declaration of Helsinki and approval of the enrolment as well as the usage of patient blood samples for research purpose will be obtained from the institutional ethics committee, and written informed consent will be obtained from all patients.The primary analysis upon which the sample size consideration was based involved the comparison of the SVR subgroup and the subgroup of patients without SVR. For the sample size calculation, we a two-factorial design (time course × SVR) with the use of a two-way analysis of variance (ANOVA) analysis, a significance level of 5% and a statistical power of at least 80% to detect a medium effect size (d = 0.5) and thus to show a significant group difference. Based on this background, the optimal sample size is calculated to be a total of 102 subjects. To consider asymmetric subgroups and to allow for a moderate dropout rate and additional calculations (secondary study objectives), we aim to include a total of at least 150 study participants in each group with 25 healthy volunteers as controls.

Connect with a study center

Postgraduate Institute of Medical Education and Research
Chandigarh, 160012
India
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.